CLINICAL COURSE AND TREATMENT CHARACTERISTICS OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AND METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE
Published: 2026-04-18
Abstract
Metabolic dysfunction-associated fatty liver disease (MAFLD/MASLD) affects up to 38% of the global adult population and more than 70% of individuals with type 2 diabetes mellitus (T2DM). The coexistence of these conditions increases the risks of cirrhosis, hepatocellular carcinoma, and major cardiovascular events.
List of references
About the Authors
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
[1]
Farzona Aripdzhanova tran. 2026. CLINICAL COURSE AND TREATMENT CHARACTERISTICS OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AND METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE. Uzbekistan Open Conference. 11 (Apr. 2026).